Related Experiment Video
Updated: Jan 7, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.3K
Thyroid dysfunction in heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Maryam Heidarpour1, Mania Banar1, Amir Parsa Abhari2
1Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atherosclerosis
|December 31, 2025
Summary
Thyroid dysfunction is common in patients with heart failure with preserved ejection fraction (HFpEF). This systematic review found a 15% prevalence of overt thyroid dysfunction and 22% for low T3 syndrome in HFpEF patients.
Area of Science:
- Cardiology
- Endocrinology
- Internal Medicine
Background:
- Thyroid dysfunction is often assumed to be linked to heart failure with preserved ejection fraction (HFpEF).
- Existing research on thyroid hormones and HFpEF presents controversial findings.
- This study systematically reviews the literature to determine the prevalence of thyroid dysfunction in HFpEF patients.
Purpose of the Study:
- To systematically review and estimate the prevalence of thyroid dysfunction in patients diagnosed with HFpEF.
- To analyze the prevalence of overt thyroid dysfunction, low T3 syndrome, and subclinical hypothyroidism (SCH) in HFpEF.
- To assess the association between thyroid dysfunction and HFpEF severity and outcomes.
Main Methods:
- A comprehensive literature search was conducted across major databases (PubMed, Scopus, Web of Science, Embase, ProQuest) up to November 2024.
- Included observational studies focused on thyroid dysfunction prevalence in HFpEF patients.
- Pooled prevalence was calculated using a random-effects model, with publication bias assessed via Trim and Fill test, funnel plot, and Egger's test.
Main Results:
- The analysis included 14 studies with 3,931 HFpEF subjects.
- The pooled prevalence of overt thyroid dysfunction was 15% (95% CI: 7%-29%).
- Prevalence rates were 22% (95% CI: 20%-25%) for low T3 syndrome and 15% (95% CI: 1%-68%) for subclinical hypothyroidism (SCH).
Conclusions:
- Thyroid dysfunction appears to be a common comorbidity in patients with HFpEF.
- Despite study heterogeneity, findings suggest a potential link between thyroid dysfunction and more severe HFpEF symptoms.
- Thyroid dysfunction may be associated with poorer outcomes in individuals with HFpEF.
Related Concept Videos
01:27Heart Failure I: Introduction
657
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
657
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
01:22Heart Failure Drugs: β-Blockers
727
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727
01:30Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763